SKI-2, a pharmacological inhibitor of SphK, diminishes the lipolysis-stimulated IL-6 expression. Pretreatment of SKI-2 (5 μm, 1 h) significantly inhibited the ADRB3 activation increased expression of IL-6 mRNA in cultured adipocytes (A) and in EWAT in animals (B). **, p < 0.01; *, p < 0.05; t test. Ctrl, control.